Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective October 1, 2024, the Compensation Committee of the Company's Board of Directors granted two newly-hired employees a total of 16,325 restricted stock units (“RSUs”) and 24,670 stock options (“options”).
- 10/04/2024
|
Assertio Holdings: Management Change Could Improve Comeback Chances
- After losing exclusivity with its prior flagship drug, pharma firm Assertio Holdings (ASRT) is angling for a comeback with a new flagship drug product. However, Assertio's latest fiscal results were mixed at best, suggesting challenges ahead with its turnaround efforts. Still, with a new CEO at the helm, there may now be greater potential for ASRT to not only experience improved fiscal performance, but experience a market re-rating as well.
- 09/11/2024
|
Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024
- LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will host investor meetings at two investor conferences taking place in New York City during September 10-12, 2024.
- 09/03/2024
|
Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript
- Assertio Holdings, Inc. (NASDAQ:ASRT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - Chief Executive Officer Ajay Patel - Senior Vice President and Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Raghuram Selvaraju - H.C. Wainwright Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners James Sidoti - Sidoti and Company Operator Thank you for standing by.
- 08/07/2024
|
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
- Assertio (ASRT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.13 per share a year ago.
- 08/07/2024
|
Assertio Reports Second Quarter 2024 Financial Results
- Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4 Million LAKE FOREST, Ill., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the second quarter ended June 30, 2024.
- 08/07/2024
|
Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
- Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/31/2024
|
Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024
- LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release second quarter 2024 financial results on Wednesday, August 7, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
- 07/24/2024
|
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- LAKE FOREST, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective July 1, 2024, the Compensation Committee of the Company's Board of Directors granted four newly-hired employees a total of 44,575 restricted stock units (“RSUs”) and 142,910 stock options (“options”).
- 07/09/2024
|
ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Assertio Holdings, Inc. (NASDAQ: ASRT) on behalf of long-term stockholders following a class action complaint that was filed against Assertio on January 5, 2024 with a Class Period from March 9, 2023 to November 8, 2023. Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.
- 07/03/2024
|
Assertio: An Extremely Asymmetric Bet Skewed To The Upside
- Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets. The merger with Spectrum Pharmaceuticals saved Assertio from potential collapse after a generic drug approval, providing a new opportunity with Rolvedon. A DCF valuation model suggests a fair equity value of $4.00 per share, indicating a potential 300% upside from the current share price, but high risks are involved.
- 06/27/2024
|
3 Penny Stocks With 458% Average Upside According to Wall Street Analysts
- Investors might be intrigued by penny stocks because they are so cheap to own. By investing $100 into a stock that trades for $0.50, you can own 200 shares of a company in your portfolio.
- 06/24/2024
|
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- LAKE FOREST, Ill., June 06, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective May 31, 2024, the Compensation Committee of the Company's Board of Directors granted the Company's new Chief Executive Officer, Brendan P. O'Grady, 500,000 restricted stock units (“RSUs”) and 1,800,000 stock options (“options”).
- 06/06/2024
|
Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024
- LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will present at the Sidoti Small Cap Conference, which will take place virtually on June 12, 2024.
- 06/05/2024
|
Assertio to Participate in Benchmark Healthcare Conference on May 21-22
- LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024.
- 05/17/2024
|
BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS
- Letter Expresses Several Significant Concerns and Recommends That Further Investigation is Warranted Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to Bylaws NEW YORK , May 17, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), today released a letter from Rumbi B. Petrozzello, a Certified Public Accountant and Certified Fraud Examiner who previously served as President of the New York State Society of CPAs.
- 05/17/2024
|
Assertio to Participate in AGP Healthcare Conference on May 21
- LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Alliance Global Partners Virtual Healthcare Company Showcase to be held virtually on May 21, 2024. Mr. Patel will present an overview of Assertio's business at 3:40 p.m. Eastern Time.
- 05/16/2024
|
BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS
- Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to Bylaws Board and Management Inappropriately Answered or Refused to Answer Questions Over Very Material Matters Believes Insiders May Have Not Personally Purchased Shares in Over Three Years Due to Material Non-Public Information Last Remaining Investor-Minded Advocate on Board Has Chosen to Step Down Over Inappropriate Boardroom Activity, Leaving a Largely Out-of-Touch Board Analysts Have Dropped Coverage of Assertio Due to What Appears to be Lost Faith in Leadership's Due Diligence Abilities, Reinforcing BHG's Concerns Intends to Imminently Release Third-Party Expert Opinions Concerning Assertio Board and Management's Apparent Disclosure Failures and Deficiencies, for Further Delivery to Regulators Believes Board Should Promptly Explore Strategic Alternatives, Including a Possible Sale, Given Significant Opportunity to Achieve Post-Acquisition Operating Profit Enhancement through Reduced SG&A Expenses NEW YORK , May 13, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) urges Assertio stockholders to vote "against" all of the Company's director nominees at the Company's upcoming 2024 annual meeting of stockholders on May 23, 2024 (the "Annual Meeting"). BHG strongly believes that significant change to the Assertio board of directors (the "Board") is necessary in order to bring about new oversight and reinstate stockholder-like judgment in the Boardroom.
- 05/13/2024
|
Assertio to Present at the Citizens JMP Life Sciences Conference in New York City
- LAKE FOREST, Ill., May 10, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference to be held May 13, 2024 in New York City.
- 05/10/2024
|
Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript
- Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO Paul Schwichtenberg - Chief Commercial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets Operator Good afternoon, and welcome to Assertio Holdings First Quarter 2024 Financial Results Call. [Operator Instructions] I would now like to turn the call over to Matt Kreps, Investor Relations for the company.
- 05/06/2024
|
Assertio Reports First Quarter 2024 Financial Results
- First Quarter Net Product Sales of $31.9 Million
- 05/06/2024
|
Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024
- LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
- 04/25/2024
|
Assertio to Present at LD Micro Invitational Conference in New York City
- LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.
- 04/01/2024
|
Assertio Holdings Inc. (ASRT) Q4 2023 Earnings Call Transcript
- Assertio Holdings Inc. (NASDAQ:ASRT ) Q4 2023 Earnings Conference Call March 11, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO Paul Schwichtenberg - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Operator Thank you for standing by, and welcome to the Assertio Holdings Fourth Quarter and Full Year 2023 Results Call. I would now like to welcome Matt Kreps, Investor Relations for the company to begin the call.
- 03/11/2024
|
Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
- Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million
- 03/11/2024
|
Assertio Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
- NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69322&wire=1 or contact Joseph E. Levi, Esq.
- 03/05/2024
|
The Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT
- NEW YORK , March 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Assertio Holdings, Inc.. Shareholders who purchased shares of ASRT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 03/05/2024
|
Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69257&wire=1 or contact Joseph E. Levi, Esq.
- 03/05/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 5, 2024 in Assertio Holdings Lawsuit - ASRT
- NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69255&wire=1 or contact Joseph E. Levi, Esq.
- 03/05/2024
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc.(ASRT) Shareholders
- NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69171&wire=1 or contact Joseph E. Levi, Esq.
- 03/04/2024
|
Assertio Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
- NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69137&wire=1 or contact Joseph E. Levi, Esq.
- 03/04/2024
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 5, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) securities between March 9, 2023 and November 8, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On August 3, 2023, the U.S. Food and Drug Administration.
- 03/04/2024
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc.(ASRT) Shareholders
- NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69120&wire=1 or contact Joseph E. Levi, Esq.
- 03/04/2024
|
Shareholders that lost money on Assertio Holdings, Inc.(ASRT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69111&wire=1 or contact Joseph E. Levi, Esq.
- 03/04/2024
|
Levi & Korsinsky Reminds Assertio Holdings Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT
- NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69107&wire=1 or contact Joseph E. Levi, Esq.
- 03/04/2024
|
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Assertio Holdings, Inc. (NASDAQ: ASRT) Investors to Inquire About a Securities Fraud Class Action by March 5, 2024
- PHILADELPHIA , March 4, 2024 /PRNewswire/ -- Nationally recognized law firm, Berger Montague PC , informs investors that a lawsuit was filed against Assertio Holdings, Inc. ("Assertio") (NASDAQ: ASRT) on behalf of purchasers of Assertio's securities between March 9, 2023 and November 8, 2023, inclusive (the "Class Period"). Investors that suffered losses from Assertio Holdings, Inc. (NASDAQ: ASRT) investments can follow the link below for more information regarding the lawsuit: CLICK HERE to learn more about the lawsuit.
- 03/04/2024
|
Assertio Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
- NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69048&wire=1 or contact Joseph E. Levi, Esq.
- 03/04/2024
|
Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
- LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, today announced that it will release fourth quarter and full year 2023 financial results on Monday, March 11, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
- 02/29/2024
|
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
- Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.
- 02/05/2024
|
Assertio Holdings: Here's A Contrarian Opportunity In The Health Care Sector
- Assertio Holdings has dropped substantially and is down more than 70% in the past year. Assertio Holdings appears to have been oversold based on quantitative factors. It trades at a very low enterprise value to revenue ratio compared to its peers. Diversification is important in managing the risk associated with distressed equities like Assertio. I'm issuing a Buy rating but suggest diversifying.
- 01/08/2024
|
Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO
- Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.
- 01/04/2024
|
Pre-Surge Penny Picks: 3 Stocks to Buy Before They Boom
- Today's backdrop of a predicted fall in interest rates, as well as the expectation that indices like the S&P 500 will surge higher, has some important considerations for penny stocks. Penny stocks tend to do better when the downward pressures on their valuations subside.
- 12/25/2023
|
Assertio Holdings Inc. (ASRT) Q3 2023 Earnings Call Transcript
- Assertio Holdings Inc. (NASDAQ:ASRT ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, IR Dan Peisert - President and CEO Ajay Patel - SVP & Chief Accounting Officer Paul Schwichtenberg - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Jim Sidoti - Sidoti Scott Henry - ROTH MKM Partners Operator Good morning and welcome to the Assertio Holdings Inc. Third Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.
- 11/08/2023
|
Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023
- LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
- 11/02/2023
|
Assertio Holdings: Uncovering A Tapestry Of Trading Opportunities From This Oversold Ticker
- Assertio Holdings has undergone a significant transformation in its business model, reducing debt and exiting the opioid business. The company's recent performance has shown strong growth, with increased net product sales and improved gross margin. Assertio's stock is currently undervalued, trading at a significant discount, and has the potential for future growth and a turnaround.
- 10/15/2023
|
Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?
- Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
- 09/22/2023
|
Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?
- Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
- 08/23/2023
|
Why Is Assertio (ASRT) Stock Down 46% Today?
- Assertio (NASDAQ: ASRT ) stock is falling hard on Friday after the pharmaceutical company released its Q2 earnings report. Assertio disappointed investors with its adjusted earnings per share of 19 cents.
- 08/04/2023
|
Assertio Holdings Is Back As A High-Value Play
- The stock is down 33% from its 52-week high. Q2 revenue estimates are low. Lead product's use may be expanding.
- 07/26/2023
|
Buy Spectrum Pharmaceuticals For Exposure To Assertio Holdings
- Spectrum stockholders will receive contingent value rights, too, along with Assertio shares. The rewards are payable on achievement of 2024 and 2025 sales levels from Spectrum's lead drug. Rolvedon has already reached the first (hardest) target in Q1 without the help of a J-Code that took effect at the beginning of Q2.
- 07/24/2023
|
3 Cheap Penny Stocks to Buy Before They Bounce Back
- The Supreme Court recently nullified the Biden administration's proposed student loan forgiveness program in a 6-3 ruling. Seen as overreaching the authority of the executive branch, this program intended to forgive nearly $430 billion in loans.
- 07/07/2023
|
Assertio: Cheap And Growing Disruptor Of Pharma's Antiquated Sales Model
- Assertio is a late-stage pharmaceutical company that has shown significant growth and cost savings under new leadership, focusing on a low-cost, data-driven marketing model. The company's leading product, Indocin, has seen increased sales and a recent 5x market expansion not yet included in company guidance. Assertio ranks in the top 1% of stocks in both value and high-quality momentum.
- 06/20/2023
|
Assertio Holdings: Spectrum Pharmaceuticals Has A Merger Spread Plus A Free CVR
- Share portion of takeover by Assertio Holdings covers the value of the shares plus a merger spread. Contingent value rights on their drug are also included, adding up to $0.20 per share. CVR payout will require aggressive sales growth, but they're effectively free.
- 06/16/2023
|
Assertio Holdings: Promising Small Cap With Strong Financials And Strategic Plans
- Assertio Holdings, a pharmaceutical company, has demonstrated solid financials and growth potential, with a focus on reducing debt levels and increasing cash generation through strategic acquisitions. The company's liquidity position has improved over the past few years, with increasing current and cash ratios indicating a well-managed leverage condition. Despite potential risks such as increasing competition from generics and supply chain vulnerabilities, Assertio's strong financial structures and progress make it a suitable buy-rated stock.
- 06/15/2023
|
Assertio Holdings Stock Is Setting Up Again
- In Q1 FY2023, Assertio achieved significant progress in executing the new strategy brought on board by CEO Dan Peisert. The market expects ASRT's EPS to decline nearly 82% YoY in FY2023, but then rebound strongly, with a compound annual growth rate [CAGR] of 23.7% over the next 3 years. I reiterate my previous "Buy" rating and set a 12-month price target of $10.16 per share, implying an upside potential of 60% over the medium term.
- 06/05/2023
|
Assertio Holdings, Inc. (ASRT) Q1 2023 Earnings Call Transcript
- Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2023 Results Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President and Chief Executive Officer Paul Schwichtenberg - Senior Vice President and Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - ROTH Capital William Wood - B. Riley Securities Hamed Khorsand - BWS Financial Mitra Ramgopal - Sidoti & Company Operator Good afternoon and welcome to the Assertio Holdings, Inc. First Quarter 2023 Financial Results Conference Call.
- 05/09/2023
|
Artificial Intelligence Engine Predicts ASRT Stock to Gain 3% by June 1
- The world's foremost artificial intelligence stock trading algorithm, An-E, predicts that Assertio (NASDAQ: ASRT ) stock will gain 3% by June 1. An-E (pronounced Annie) has made this kind of prediction before.
- 05/04/2023
|
Assertio Holdings Stock Is Still A Cheap Buy
- Assertio Holdings stock has fallen 8.15% since my updated bullish thesis in March 2023, while the S&P 500 Index has gained 4.95% over the same period. The SPPI deal is expected to give Assertio access to Rolvedon and be accretive to adjusted EPS and operating cash flow in FY2024.
- 05/02/2023
|
Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
- LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
- 04/27/2023
|
Spectrum Pharmaceuticals stock pops after Assertio acquires it at a premium
- Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning. The $248 million purchase price values Spectrum shares at $1.14 each, a significant premium over its Tuesday closing price of $0.69.
- 04/25/2023
|
Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know
- Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 04/10/2023
|
Assertio Holdings: Spectacular Growth Story Powered By Risky Strategy
- Assertio Holdings, Inc. has impressive growth rates and an attractive valuation. The company's involvement with an opioid in the past may explain the low valuation.
- 03/28/2023
|
Eternal Sunshine: 3 Very Profitable Stocks To Buy In 2023
- Companies with strong profitability tend to have more stable earnings and cash flows, which can make them more resilient to market volatility. This article focuses on stocks with a proven track record of profitability. High-quality stocks come in all shapes and sizes regardless of their market cap.
- 03/28/2023
|
Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock
- Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
- 03/27/2023
|
Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?
- Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
- 03/14/2023
|
Assertio Holdings, Inc. (ASRT) Q4 2022 Earnings Call Transcript
- Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President & Chief Executive Officer Paul Schwichtenberg - Senior Vice President & Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Scott Henry - ROTH Capital Hamed Khorsand - BWS Financial Mitra Ramgopal - Sidoti Operator Good afternoon and welcome to the Assertio Holdings' Fourth Quarter and Full Year 2022 Financial Results Conference Call. All participants are now in listen-only mode.
- 03/08/2023
|
Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates
- Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/08/2023
|
Assertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should Know
- Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 03/03/2023
|
Why Earnings Season Could Be Great for Assertio (ASRT)
- Assertio (ASRT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/02/2023
|
Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?
- Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 03/01/2023
|
Assertio: A Truly Impressive Turnaround Story
- Assertio is a truly impressive turnaround story that is now set to grow, mostly through M&A. The crucial ingredient is the digital-only sales model, which puts acquired drugs on a much lower cost basis while maintaining sales.
- 02/28/2023
|
Assertio Holdings: Compelling Income Opportunity Apart From Upside Potential
- Q4 preliminary results illustrate the best product sales quarter for the past 5 years. Technicals, valuation, and profitability trends all point to rising prices for the stock.
- 02/24/2023
|
Assertio Holdings, Inc. (ASRT) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 02/20/2023
|
Why Assertio (ASRT) Could Beat Earnings Estimates Again
- Assertio (ASRT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 02/10/2023
|
Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know
- Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 02/08/2023
|
Assertio Holdings Scores With New Broadly-Covered Asset
- Assertio Holdings, Inc. got the rights to Sympazan in October. Most Medicare plans cover it.
- 01/20/2023
|
Assertio Holdings: This Top-Rated Stock Is Still Undervalued
- Assertio Holdings stock has shown phenomenal growth throughout 2022 - especially when compared to the S&P 500 Index and the Healthcare sector. After taking a closer look at this company, I conclude that its low valuation multiples are not just a temporary/cyclical phenomenon.
- 01/19/2023
|
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
- Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
- 01/18/2023
|
Are Medical Stocks Lagging Assertio (ASRT) This Year?
- Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
- 12/30/2022
|
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 12/26/2022
|
Is Assertio (ASRT) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/22/2022
|
Assertio Holdings: Acquiring Good Products Is The Key To Success
- Assertio Holdings is a pharmaceutical company based on a niche model that is focused on digital, non-personal promotion. Last Q3 showed great revenue and cash flow growth.
- 12/21/2022
|
10 Top Penny Stocks To Watch With High Short Interest This Week
- Short squeeze penny stocks to buy now or avoid entirely? The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/20/2022
|
The 7 Hottest Penny Stocks to Own for 2023 and Beyond
- Irrespective of the stock market's overall performance in the coming year, there are many stocks that could nonetheless “crush it” in 2023. Included in that category are some of the hottest penny stocks out there right now.
- 12/15/2022
|
Are Medical Stocks Lagging Assertio (ASRT) This Year?
- Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
- 12/14/2022
|
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 11/23/2022
|
Should Value Investors Buy Assertio (ASRT) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 11/22/2022
|
Assertio Holdings, Inc. (ASRT) Q3 2022 Earnings Call Transcript
- Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, Investor Relations Daniel Peisert - President & Chief Executive Officer Paul Schwichtenberg - Senior Vice President & Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Scott Henry - ROTH Capital Mitra Ramgopal - Sidoti Hamed Khorsand - BWS Financial Scott Weis - Senko Operator Good morning and welcome to the Assertio Holdings, Inc. Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] Note this event is being recorded.
- 11/08/2022
|
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 11/07/2022
|
My Top 5 U.S. Stocks Under $10
- After a rough September, we're approaching the season historically known for stronger performance. Although small-cap stocks can be more volatile than large-caps, cheap stocks often have high return potential. Offering attractive valuations, above-average growth, and strong balance sheets, our Quant-based picks under $10 have vastly outperformed both Large and Small-cap indexes.
- 11/03/2022
|
Are Investors Undervaluing Assertio (ASRT) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 11/01/2022
|
Best Penny Stocks To Buy? 4 To Watch Before November
- Penny stocks to watch before November 2022 The post Best Penny Stocks To Buy? 4 To Watch Before November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/28/2022
|
Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
- LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2022 financial results on Tuesday, November 8, 2022, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
- 10/27/2022
|
3 Small-Cap Pharma Stocks For A 2022 Melt-Up
- This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile price swings that include declines of more than 20% in the major indexes are prompting investors to consider defensive investments.
- 10/27/2022
|
The 7 Best Penny Stocks to Buy Now
- As stocks remain in a bear market, even the best penny stocks continue to trade at depressed price levels. With macro uncertainties like inflation, rising interest rates, and a possible recession still looming, investors are reluctant to dive into these names, which are typically more risky and volatile than large-cap stocks.
- 10/26/2022
|
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
- Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.
- 10/25/2022
|
ASRT or UTHR: Which Is the Better Value Stock Right Now?
- ASRT vs. UTHR: Which Stock Is the Better Value Option?
- 10/21/2022
|
Assertio to Participate in October 2022 Investor Conferences
- LAKE FOREST, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that management will participate at the following investor conference events during October 2022.
- 10/12/2022
|
Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock
- Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 10/07/2022
|
ASRT vs. STVN: Which Stock Is the Better Value Option?
- ASRT vs. STVN: Which Stock Is the Better Value Option?
- 10/03/2022
|
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
- Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.
- 09/28/2022
|
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
- These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market in some segments of the market even during these gloomy weeks.
- 09/27/2022
|
Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?
- Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 09/26/2022
|
Down 18.3% in 4 Weeks, Here's Why Assertio (ASRT) Looks Ripe for a Turnaround
- Assertio (ASRT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 09/21/2022
|
Assertio (ASRT) Flat As Market Sinks: What You Should Know
- Assertio (ASRT) closed at $2.24 in the latest trading session, marking no change from the prior day.
- 09/20/2022
|
ASRT vs. STVN: Which Stock Should Value Investors Buy Now?
- ASRT vs. STVN: Which Stock Is the Better Value Option?
- 09/14/2022
|
Is Most-Watched Stock Assertio Holdings, Inc. (ASRT) Worth Betting on Now?
- Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
- 09/13/2022
|
Assertio Holdings Looks Good To Rebound After Recent Price Plunge
- Assertio beat on Q2 revenue and earnings and revised guidance upwards. They negotiated debt to save $4.5 million in annual payments.
- 09/07/2022
|
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
- Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
- 09/07/2022
|
Assertio (ASRT) Upgraded to Buy: Here's Why
- Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 08/30/2022
|
ASRT or CORT: Which Is the Better Value Stock Right Now?
- ASRT vs. CORT: Which Stock Is the Better Value Option?
- 08/25/2022
|
Assertio Holdings: Substantial Upside
- Assertio Holdings has expanding sales and strong margins. ASRT is making moves to save money on debt servicing with strong cash on hand.
- 08/21/2022
|
Assertio Holdings, Inc. (ASRT) CEO Daniel Peisert on Q2 2022 Results - Earnings Call Transcript
- Assertio Holdings, Inc. (NASDAQ:ASRT ) Q2 2022 Earnings Conference Call August 8, 2022 11:30 AM ET Company Participants Matthew Kreps - Darrow Associates, IR Daniel Peisert - President and CEO Paul Schwichtenberg - SVP and CFO Conference Call Participants Scott Henry - ROTH Capital Mitra Ramgopal - Sidoti Hamed Khorsand - BWS Financial Thomas Flaten - Lake Street Capital Scott Weis - Semco Operator Hello, everyone, and welcome to the Assertio Holdings Q2 Earnings Call. My name is Emily, and I'll be moderating the call today.
- 08/08/2022
|
Assertio (ASRT) Q2 Earnings and Revenues Top Estimates
- Assertio (ASRT) delivered earnings and revenue surprises of 100% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
- Here is how Assertio (ASRT) and Shockwave Medical (SWAV) have performed compared to their sector so far this year.
- 08/05/2022
|
ASRT vs. CTLT: Which Stock Is the Better Value Option?
- ASRT vs. CTLT: Which Stock Is the Better Value Option?
- 08/04/2022
|
7 Penny Stocks to Buy Before the Bull Market Returns
- In recent weeks, the stock market has stabilized after June's sell-off, but it may take time before bullishness makes a comeback. Plenty of uncertainty remains, including further interest rate hikes, continued high inflation, and the growing chance of a recession.
- 08/01/2022
|
Hot Penny Stocks To Buy? 4 Under $3 To Watch This Week
- Are you looking for some hot penny stocks to buy this week?
- 07/25/2022
|
Assertio Holdings, Inc. To Report Second Quarter 2022 Financial Results on Monday, August 8, 2022
- LAKE FOREST, Ill., July 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release second quarter 2022 financial results on Monday, August 8, 2022, before the market open. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 11:30 a.m. Eastern Time.
- 07/25/2022
|
3 Best Breakout Stocks to Invest in for Attractive Returns
- Assertio (ASRT), Mercer International (MERC) and The LGL Group (LGL) have been selected as the breakout stocks for today.
- 07/21/2022
|
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 07/18/2022
|
Here's Why Assertio Holdings (ASRT) Stock is Up This Year
- Assertio Holdings' (ASRT) successful execution of its restructuring plan, resulting in significant cost savings, is boosting profits.
- 07/07/2022
|
4 Small Stocks to Bet on in an Upbeat Drugs Industry
- It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.
- 07/06/2022
|
3 Top Stocks That Stand to Gain From a Stronger Dollar
- Stocks such as Assertio Holdings (ASRT), Clipper Realty (CLPR) and Consolidated Water (CWCO) should benefit as the dollar strengthens against its key counterparts.
- 07/06/2022
|
Beat the Market Like Zacks: Assertio, Brookfield, UnitedHealth, General Mills in Focus
- Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
- 07/05/2022
|
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
- Here is how Assertio (ASRT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
- 07/04/2022
|
ASRT or ZTS: Which Is the Better Value Stock Right Now?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 06/29/2022
|
New Strong Buy Stocks for June 21st
- IMO, ASRT, LPX, EGLE, and CAL have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2022.
- 06/21/2022
|
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 06/13/2022
|
New Strong Buy Stocks for June 10th
- SBLK, SSB, HCI, ASRT, and TTI have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2022.
- 06/10/2022
|
7 Best Penny Stocks to Buy Now for Moonshot Potential
- In a tough 2022 year for the stock market, these penny stocks could be on the cusp of market-beating gains. The post 7 Best Penny Stocks to Buy Now for Moonshot Potential appeared first on InvestorPlace.
- 06/10/2022
|
New Strong Buy Stocks for June 7th
- SBLK, GOGL, LPX, ASRT, and CC have been added to the Zacks Rank #1 (Strong Buy) List on June 7, 2022.
- 06/07/2022
|
Are Medical Stocks Lagging Assertio (ASRT) This Year?
- Here is how Assertio (ASRT) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
- 05/30/2022
|
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
- ASRT vs. ZTS: Which Stock Is the Better Value Option?
- 05/26/2022
|
Assertio's Phenomenal Turnaround
- The company has made giant strides in putting its financials in order, getting rid of almost $1B in debt and its net debt has been all but eliminated. We believe more is to come as the company's all-digital business model is very scalable.
- 05/19/2022
|
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
- Here is how Assertio (ASRT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
- 05/13/2022
|
Assertio Posts Higher Q1 Sales, Profits; Lifts FY22 Adjusted EBITDA Outlook
- Assertio Holdings Inc (NASDAQ: ASRT) posted Q1 sales of $35.5 million, up 37% Y/Y, surpassing the consensus of $33.06 million. The increase was primarily driven by higher net pricing on Indocin and the addition of Otrexup.
- 05/10/2022
|
Assertio Holdings, Inc. (ASRT) CEO Daniel Peisert on Q1 2022 Results - Earnings Call Transcript
- Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Max Nemmers - Head, Investor Relations and Administration Daniel Peisert - President & CEO Paul Schwichtenberg - SVP & CFO Conference Call Participants Scott Weis - Semco Capital Operator Good morning and welcome to the Assertio Holdings, Inc. First Quarter 2022 Financial Results Conference Call. All participants will be in listening-only mode.
- 05/09/2022
|
Assertio (ASRT) Surpasses Q1 Earnings and Revenue Estimates
- Assertio (ASRT) delivered earnings and revenue surprises of 122.22% and 10.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Assertio Holdings, Inc. to Report First Quarter 2022 Financial Results After the Close of Markets on Monday, May 9, 2022
- LAKE FOREST, Ill., April 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2022 financial results on Monday, May 9, 2022, after the close of markets. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. eastern time.
- 04/22/2022
|
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
- Here is how Assertio (ASRT) and Histogen Inc (HSTO) have performed compared to their sector so far this year.
- 04/13/2022
|
Best Value Stocks to Buy for April 13th
- WFG, GOGL, and ASRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 13, 2022.
- 04/13/2022
|
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
- Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
- 04/08/2022
|
Assertio Holdings: Recent Breakout To Lead To Sustained Gains
- Company grows the top-line by 7% in Q4 due to strong performances from Indocin, Cambia & Zipsor.
- 04/07/2022
|
5 Cheap Stocks Under $10 To Buy Now
- 5 Cheap Stocks Under $10 To Buy Now
- 04/04/2022
|
3 Top Breakout Stocks to Invest In for Solid Returns
- Assertio Holdings, Inc. (ASRT), VAALCO Energy, Inc. (EGY) and DLH Holdings Corp. (DLHC) have been selected as the breakout stocks for today.
- 03/31/2022
|
New Strong Buy Stocks for March 24th
- ASRT, CPRI, GRIN, OCDX, and KN have been added to the Zacks Rank #1 (Strong Buy) List on March 24, 2022.
- 03/24/2022
|
New Strong Buy Stocks for March 15th
- CPRI, GOGL, EOG, ASRT, and IMO have been added to the Zacks Rank #1 (Strong Buy) List on March 15, 2022.
- 03/15/2022
|
Top 5 High-Flying Small Hidden Gems Amid Wall Street Mayhem
- We have narrowed our search to five small-cap stocks that have provided double-digit returns year to date. These are: USAK, TMST, JAKK, UFCS and ASRT.
- 03/11/2022
|
Assertio (ASRT) Q4 Earnings Lag Estimates
- Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/09/2022
|
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
- Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.
- 03/02/2022
|
JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs
- JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
- 03/02/2022
|
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results Before the Opening of Markets on Wednesday, March 9, 2022
- LAKE FOREST, Ill., March 02, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2021 financial results on Wednesday, March 9, 2022, before the open of markets. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 9:00 a.m. eastern time.
- 03/02/2022
|
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
- Here is how Assertio (ASRT) and Homology Medicines (FIXX) have performed compared to their sector so far this year.
- 02/21/2022
|
Assertio: A Turnaround Where Almost Everything Just Changed
- After years of losses and declining revenues, new management was brought in a year ago. Assertio looks almost entirely different than two years ago.
- 01/21/2022
|
Assertio's Digital Strategy Looks To Be Paying Off
- Assertio's Digital Strategy Looks To Be Paying Off
- 01/21/2022
|
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
- Here is how Assertio (ASRT) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
- 01/10/2022
|
Despite Fast-paced Momentum, Assertio (ASRT) Is Still a Bargain Stock
- Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 12/28/2021
|
Do Options Traders Know Something About Assertio (ASRT) Stock We Don't?
- Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
- 12/20/2021
|
Assertio Shares Gain After Buying Antares' Rheumatoid Arthritis Treatment For $44M
- Antares Pharma Inc (NASDAQ: ATRS) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary of Assertio Holdings Inc (NASDAQ: ASRT) for $44 million inclusive of Otrexup WIP and finished inventory. Under the asset purchase agreement terms, Antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totaling $26.0 million in 2022.
- 12/16/2021
|
Assertio (ASRT) Shows Fast-paced Momentum But Is Still a Bargain Stock
- Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 11/16/2021
|
Assertio Holdings (ASRT) Stock: Why The Price Jumped Today
- The stock price of Assertio Holdings Inc (NASDAQ: ASRT) increased by over 27% during intraday trading today. This is why it happened.
- 11/05/2021
|
Assertio Posts Higher Profitability In Q3 Despite Lower Revenues
- Assertio Holdings Inc (NASDAQ: ASRT) posted Q3 sales of $25.9 million, down 23% Y/Y, but surpassed the consensus of $22.04 million. Assertio's restructuring plan resulted in cost savings of $40.0 million in 2021.
- 11/05/2021
|
Assertio Holdings' (ASRT) CEO Dan Peisert on Q3 2021 Results - Earnings Call Transcript
- Assertio Holdings' (ASRT) CEO Dan Peisert on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates
- Assertio (ASRT) delivered earnings and revenue surprises of 300.00% and 15.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Assertio Holdings, Inc. to Report Third Quarter 2021 Financial Results After the Close of Markets on Thursday, November 4, 2021
- LAKE FOREST, Ill., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release third quarter 2021 financial results on Thursday, November 4, 2021, after the close of markets. Following the release of its financial results, Assertio's management will host a conference call beginning at 4:30 p.m. eastern time.
- 10/26/2021
|
Assertio Holdings, Inc. to Participate in Upcoming Investor Events
- LAKE FOREST, Ill., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT) today announced that the Company's Chief Executive Officer, Dan Peisert, and Chief Financial Officer, Paul Schwichtenberg, will present and host individual meetings with investors at the following events:
- 10/04/2021
|
Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q2 2021 Results - Earnings Call Transcript
- Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
- Assertio (ASRT) delivered earnings and revenue surprises of -300.00% and 24.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Assertio Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
- LAKE FOREST, Ill., June 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”). Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and this matter is now closed.
- 06/04/2021
|
Assertio Holdings, Inc. Announces 1-for-4 Reverse Stock Split
- LAKE FOREST, Ill., May 17, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has filed a Certificate of Amendment to its certificate of incorporation (the “Certificate of Amendment”) to implement a one-to-four reverse split of its issued and outstanding common stock (the “Reverse Split”). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on May 18, 2021, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on May 18, 2021.
- 05/17/2021
|
Assertio Holdings, Inc. Announces Adjournment of Annual Meeting of Shareholders
- - Adjournment Solely to Vote on the Reverse Split and Proportional Authorized Shares Reduction Proposal (Proposal 2) and Increase in Authorized Shares Proposal (Proposal 3)
- 05/17/2021
|
3 Penny Stocks That Investors Need to Watch In 2021
- Which penny stocks should you know about in 2021? Take a look at these 3 The post 3 Penny Stocks That Investors Need to Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/07/2021
|
ASRT Stock: Over 30% Increase Pre-Market Explanation
- The stock price of Assertio Holdings Inc (NASDAQ: ASRT) increased by over 30% pre-market. This is why it happened.
- 05/07/2021
|
Assertio Holdings' (ASRT) CEO Dan Peisert on Q1 2021 Results - Earnings Call Transcript
- Assertio Holdings' (ASRT) CEO Dan Peisert on Q1 2021 Results - Earnings Call Transcript
- 05/06/2021
|
Assertio Holdings, Inc. to Report First Quarter 2021 Financial Results After the Close of Markets on Thursday, May 6, 2021
- LAKE FOREST, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2021 financial results on Thursday, May 6, 2021, after the close of markets. Following the release of its financial results, Assertio's management will host a conference call beginning at 4:30 p.m. eastern time.
- 04/22/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Thursday
- It's never a dull day on the Reddit Penny Stocks subreddit and we're checking in to see what's being talked about the most today. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared first on InvestorPlace.
- 04/15/2021
|
Assertio Holdings: Bankruptcy, Sale Or Success - How Management Can Rapidly Deliver Triple-Digit Upside
- Assertio has endured a difficult few years that began with its $1.5bn purchase of opioid treatment Nucynta in 2015 under its former name DepoMed.
- 03/16/2021
|
Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options
- Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.
- 03/15/2021
|
Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q4 2020 Results - Earnings Call Transcript
- Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q4 2020 Results - Earnings Call Transcript
- 03/11/2021
|
Assertio Reports Fourth Quarter and Full Year 2020 Financial Results
- Full Year Net Product Sales of $93.5 Million; Full Year Pro-Forma Revenue of $119.2 Million in Line with Guidance
- 03/11/2021
|
Assertio (ASRT) Reports Next Week: What to Expect
- Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/04/2021
|
Assertio Holdings, Inc. to Present at Virtual Roth Conference on Monday, March 15, 2021
- LAKE FOREST, Ill., March 01, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that Dan Peisert, President and Chief Executive Officer of Assertio, will present at and participate in investor meetings at the 33rd Annual Roth Conference, held virtually, on Monday, March 15, 2021.
- 03/01/2021
|
Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million
- LAKE FOREST, Ill., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of common stock at a purchase price of $0.98 per share for gross proceeds of approximately $34.3 million.
- 02/12/2021
|
Do Options Traders Know Something About Assertio (ASRT) Stock We Don't?
- Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
- 02/11/2021
|
Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering
- LAKE FOREST, Ill., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 35,000,000 shares of its common stock at a price of $0.98 per share, which is a premium to market based on applicable Nasdaq “minimum price” rules.
- 02/10/2021
|
Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $14 Million
- LAKE FOREST, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of common stock at a purchase price of $0.62 per share for gross proceeds of approximately $14.0 million.
- 02/09/2021
|
Assertio Seeks To Raise $14M Via Equity At 21% Discount From Thursday's Close
- Assertio Holdings Inc (NASDAQ: ASRT) has entered into a securities purchase agreement with certain institutional investors to purchase 22.6 million common shares at $0.62 per share in a registered direct offering, for gross proceeds of $14 million. The offer price represents a discount of 21% from the last close price of $0.78 on Thursday.
- 02/05/2021
|
Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering
- LAKE FOREST, Ill., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 22,600,000 shares of its common stock at a purchase price of $0.62 per share in a registered direct offering.
- 02/05/2021
|
Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates
- LAKE FOREST, Ill., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that its subsidiary Assertio Therapeutics, Inc. (“Assertio Therapeutics”) entered into a Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) with its primary product liability insurer, Navigators Specialty Insurance Company and Navigators Insurance Company (“Navigators”).
- 02/03/2021
|
Are Options Traders Betting on a Big Move in Assertio Holdings (ASRT) Stock?
- Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.
- 01/12/2021
|
Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market
- Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing
- 12/29/2020
|
Assertio to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
- LAKE FOREST, Ill., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief executive officer and director, Todd Smith will present at and participate in investor meetings at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020. The presentation will take place at 11:20 am ET
- 11/10/2020
|
Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q3 2020 Results - Earnings Call Transcript
- Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q3 2020 Results - Earnings Call Transcript
- 11/06/2020
|
Canada's Maple Leaf suspends pork exports to China amid COVID-19 outbreak at Manitoba plant
- Canadian meat processor Maple Leaf Foods Inc has voluntarily suspended exports of pork to China following an outbreak of COVID-19 in a Manitoba plant. The company said late Tuesday that it was proactively complying with new Chinese government protocols for Canadian processors that require that any plant reporting a positive COVID-19 case suspend exports to China temporarily. "We respect China's new import protocols for Canadian products and are working cooperatively with Canadian and Chinese authorities to resume exports quickly," Maple Leaf chief executive Michael McCain said in a statement.
- 08/19/2020
|
Maple Leaf Foods Provides Update on COVID-19 at Brandon Plant
- Maple Leaf Foods Inc. (TSX: MFI) is continuing its rigorous safety efforts at its Brandon, Manitoba, plant to prevent workplace transmission amidst the recent COVID-19 cluster occurring in the community. The plant continues to operate safely, and Public Health experts have said on numerous occasions that there is no evidence of workplace transmission occurring at the plant.
- 08/19/2020
|
Media Advisory - Maple Leaf Foods Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
- TSX: MFI www.mapleleaffoods.
- 08/11/2020
|
Assertio (ASRT) Reports Q2 Loss, Misses Revenue Estimates
- Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/07/2020
|
Recap: Assertio Holdings Q2 Earnings
- Shares of Assertio Holdings (NASDAQ:ASRT) moved higher by 0.9% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 33.33% over the past year to ($0.28), which missed the estimate of ($0.03).Revenue of $20,617,000 decreased by 63.96% from the same period last year, which missed the estimate of $25,330,000.Outlook Assertio Holdings hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Aug 07, 2020View more earnings on ASRTTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/onwswjojPrice Action Company's 52-week high was at $2.9452-week low: $0.55Price action over last quarter: Up 16.49%Company Overview Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.See more from Benzinga * Earnings Scheduled For August 7, 2020 * Preview: Assertio Therapeutics's Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/07/2020
|
Assertio Reports Second Quarter 2020 Financial Results
- \--Completed all merger and integration activities in Q2-- \--Repaid $10 million of Senior Secured Notes ahead of schedule-- \--Zyla products partially contributed to Q2 net product sales of $20.2 million-- \--Combined second quarter 2020 net product sales of $27.7 million, on a pro forma basis, increased modestly over pro forma first quarter 2020 despite COVID-19 and merger integration--LAKE FOREST, Ill., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. During the second quarter, Assertio completed its merger with Zyla Life Sciences (“Zyla”).“Even in what has been an unprecedented time with patient volume and elective surgeries down due to COVID-19, we completed our merger and achieved second quarter 2020 pro forma net product sales of $27.7 million—slightly ahead of pro forma net product sales for the first quarter of 2020 and better than what we had expected,” said Todd Smith, president and chief executive officer. “During the quarter, we launched our new commercial strategy which included establishing a Neurology-focused sales team, training our sales force on our combined portfolio and improving our distribution. In addition, we established a medical science liaison team to gather medical insights and provide access to current scientific information about our products. Along with commercial execution, we believe we are in a strong financial and operational position to focus on bringing in additional products.” Pro Forma Projections for 2020 * Assertio is projecting mid-to-high-single digit pro forma net product sales growth for 2020 from the 2019 pro forma net product sales of $126.3 million. * The Company is projecting pro forma non-GAAP adjusted EBITDA margin of greater than 25 percent for the full year 2020. * The Company is on track to recognize $40.0 million annually in projected synergies from the merger with Zyla.2020 Second Quarter and Recent Financial Highlights * Payments received. Assertio negotiated with Golf Acquiror LLC, an affiliate to Alvogen, Inc. to advance its payment of all remaining royalties owed to Assertio for the sale of Gralise® (gabapentin), accelerating the collection of $38.8 million, net of discount, in the second quarter. Additionally in May 2020, the Company sold its Collegium warrants for $6.0 million. * Debt reductions. Assertio paid down $76.7 million of its convertible debt upon the close of the merger with Zyla, and $13.0 million of Zyla’s debt was extinguished. In addition, the Company repaid $10.0 million of the Senior Secured Notes in July. * Net product sales. The Company achieved $27.7 million in second quarter 2020 pro forma net product sales which was slightly above the first quarter 2020 pro forma net product sales. Zyla net product sales only partially contributed to second quarter net product sales of $20.2 million since the merger closed on May 20, 2020. * Cash position. The Company ended the second quarter with $59.4 million in cash and cash equivalents, a 40 plus percent increase over year-end 2019. 2020 Second Quarter Business Highlights * The Company closed its merger with Zyla on May 20, 2020 and effectively completed the integration of the two companies in the second quarter. * Zyla and Assertio merged the two sales forces into one, educated its representatives on the combined product portfolio, provided new healthcare provider targets to the representatives and began promotion to healthcare providers. * The Company launched a Neurology sales team focused on promotion of Cambia® (diclofenac potassium) for Oral solution and SPRIX® (ketorolac tromethamine) Nasal Spray to key prescribers who treat migraines and pain associated with headaches. * The Company established a medical science liaison team to support the further development and education of INDOCIN® (indomethacin) Oral Suspension and Suppositories. * Assertio launched a new distribution approach for SPRIX that was designed to decrease the amount of time needed to fill prescriptions and reduce costs.COVID-19Assertio continues to closely monitor the COVID-19 pandemic and its impact on the patients who are treated with the Company's products and the communities where it operates. Over the past quarter, the Company has taken steps to help minimize the spread of COVID-19 and at the same time, is working to ensure continued patient access to its medicines. Because COVID-19 impacted the Company’s ability to make office visits to providers who prescribe its products, the Company adapted its approach and increased virtual visits. Due to the limitations on elective surgeries, Assertio experienced a decline in prescriptions associated with those elective procedures. The Company believes that it is prepared with sufficient product inventory, technology to facilitate virtual office visits and operations prepared to adapt its work environment as needed.Earnings Conference Call InformationAssertio’s management will host a conference call to discuss the second quarter 2020 financial results today:Date:Friday, August 7, 2020 Time:8:30 a.m. ET Webcast (live and archive):assertiotx.com (Events & Webcasts, Investor page) Dial-in numbers:1-877-870-4263 (domestic) 1-412-317-0790 (international) Replay numbers:1-877-344-7529 (domestic) 1-412-317-0088 (international) Conference number:10134065 The live webcast and replay may be accessed at http://investor.assertiotx.com/. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Individuals also may participate in the call by dialing 1-888-346-2615 (domestic) or 1-412-902-4253 (international) and asking for the "Assertio Q2 Earnings Call." The replay will be available approximately two hours after the call on the Assertio website. About Assertio Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital and pain and inflammation. Assertio has grown through business development including licensing, mergers and acquisitions. The Company seeks to leverage its commercial excellence to be the partner of choice. To learn more about Assertio, visit www.assertiotx.com.Forward Looking Statements Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio's current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio. All statements other than historical facts may be forward-looking statements and can be identified by words such as "anticipate," "believe," "could," "design," "estimate," "expect," "forecast," "goal," "guidance," "imply," "intend," "may", "objective," "opportunity," "outlook," "plan," "position," "potential," "predict," "project," "prospective," "pursue," "seek," "should," "strategy," "target," "would," "will," "aim" or other similar expressions that convey the uncertainty of future events or outcomes are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio.
- 08/07/2020
|
Preview: Assertio Therapeutics's Earnings
- Assertio Therapeutics (NASDAQ: ASRT) will be releasing its next round of earnings this Friday, August 07. For all of the relevant information, here is your guide for Friday's Q2 earnings announcement.Earnings and Revenue Wall Street expects an EPS loss $-0.03 and sales around $25.33 million. In the same quarter last year, Assertio Therapeutics reported earnings per share of $0.25 on sales of $57.20 million. The Wall Street estimate would represent a 112.0% decline in the company's earnings. Here's how the company's reported EPS has stacked up against analyst estimates in the past:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate -0.08 0.14 0.24 0.24 EPS Actual 0.10 -0.14 0.24 0.25 Revenue Estimate 11.30 M 50.30 M 60.74 M 59.05 M Revenue Actual 20.92 M 59.23 M 55.15 M 57.20 M Stock Performance Over the last 52-week period, shares are down 38.04%. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release.View more earnings on ASRTDon't be surprised to see the stock move on comments made during its conference call. Assertio Therapeutics is scheduled to hold the call at 08:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/onwswjojSee more from Benzinga * A Preview Of Cannae Holdings's Earnings * Earnings Outlook For Essent Gr * Earnings Outlook for Twin Disc(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/06/2020
|
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
- Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/31/2020
|
Maple Leaf Foods Reports Second Quarter 2020 Financial Results
- TSX: MFI www.mapleleaffoods.
- 07/30/2020
|
Maple Leaf Foods Closes Sale of Drummondville Poultry Plant to Giannone Poultry
- MISSISSAUGA, ON, July 28, 2020 /CNW/ - Maple Leaf Foods Inc., (TSX: MFI) today announced that it has completed the previously announced sale of its poultry plant in Drummondville, Quebec, including the associated supply, to Giannone Poultry of St.
- 07/28/2020
|
Maple Leaf Foods Names Nadia Theodore Senior Vice President of Industry and Global Government Relations
- Maple Leaf Foods (TSX: MFI) today named Nadia Theodore as Senior Vice President of Global Industry and Government Relations effective October 13. Theodore will succeed Rory McAlpine, who will retire after 15 years with Maple Leaf Foods.
- 07/27/2020
|
Maple Leaf Foods' (TSE:MFI) Shareholders Are Down 21% On Their Shares
- For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...
- 07/24/2020
|
Summers Value Partners Q2 2020 Investor Letter
- Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate.
- 07/21/2020
|
Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020
- LAKE FOREST, Ill., July 20, 2020 -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020.
- 07/20/2020
|
Maple Leaf Foods Announces Sale of Drummondville Poultry Plant to Giannone Poultry
- Maple Leaf Foods Inc., (TSX: MFI) today announced the sale of its poultry plant in Drummondville, Quebec, and associated supply, to Giannone Poultry of St. Cuthbert, Quebec. As part of the sale, Maple Leaf Foods and Giannone have reached a three-year supply agreement that will allow Maple Leaf Foods to maintain its supply of fresh chicken.
- 07/16/2020
|
Media Advisory - Maple Leaf Foods Inc. 2020 Second Quarter Financial Results Conference Call
- Maple Leaf Foods Inc. will report its financial results for the second quarter 2020 on July 30, 2020. The financial results will be released by CNW newswire service at approximately 6:30 am ET, followed by a conference call at 8:00 am ET.
- 07/16/2020
|
C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
- C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
- 07/15/2020
|
Maple Leaf Foods Releases 2019 Sustainability Report
- Today, Maple Leaf Foods, Inc., (TSX: MFI) announced the release of its 2019 Sustainability Report, outlining the company's key programs and achievements during the past year, as well as future initiatives and priorities supporting Maple Leaf Foods' purposeful journey to be the most sustainable protein company on earth.
- 07/08/2020
|
Should You Avoid Assertio Holdings, Inc. (ASRT)?
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 06/30/2020
|
Analysis of COVID-19 Impact: Neuropathy Pain Treatment Market 2020-2024 | Presence of Large Patient Pool to Augment Growth | Technavio
- The Global Neuropathy Pain Treatment Market will grow by USD 1702.89 mn during 2020-2024
- 06/30/2020
|
Collegium Pharmaceutical (COLL) Gets a Buy Rating from Needham - Markets
- In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report),
- 06/26/2020
|
Maple Leaf Foods Inc. Announces Results of Vote For Election of Directors
- Maple Leaf Foods Inc. reports that at its Annual Meeting of shareholders on June 24, 2020 there were 528 shareholders voting in person and by proxy holding in total 104,396,595 Voting Common Shares, being 84.27% of the total number of Voting Common Shares outstanding.
- 06/24/2020
|
Collegium Pharmaceutical (COLL) Gets a Buy Rating from Needham - Markets
- In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report),
- 06/19/2020
|
STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Assertio Therapeutics, Inc. - ASRT
- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Assertio Therapeutics, Inc. ("Assertio Therapeutics" or the "Company") (NasdaqGS: ASRT) relating to the creation of a combined company between the Company and Zyla Life Sciences. Under the terms of the agreement, Assertio Therapeutics will issue 2.5 shares to each Zyla stockholder. Assertio Therapeutics stockholders will own 68% and Zyla stockholders will own 32% of the combined company.
- 05/22/2020
|
Maple Leaf Foods Receives TSX Approval To Proceed With Normal Course Issuer Bid
- Maple Leaf Foods Inc. (the "Company") today announced that the Toronto Stock Exchange (the "TSX") has accepted the notice filed by the Company to establish a normal course issuer bid ("NCIB") program.
- 05/21/2020
|
World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer - ResearchAndMarkets.com
|
Maple Leaf Foods Management Information Circular Now Available
- Maple Leaf Foods Inc. (the "Company") today announced that it has filed its 2020 notice of annual meeting of shareholders and management information circular and copies are now available online at www.mapleleaffoods.com and on SEDAR at www.sedar.com.
- 05/20/2020
|
Assertio Completed Merger with Zyla Life Sciences
- Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc., ("Assertio" ) (NASDAQ: ASRT) announced the closing of the merger with Zyla Life Sciences. The combined company (the "Company") will operate under the Assertio name and trade on Nasdaq under the ticker ASRT.
- 05/20/2020
|
One Analyst's Earnings Estimates For Assertio Therapeutics, Inc. (NASDAQ:ASRT) Are Surging Higher
- Assertio Therapeutics, Inc. (NASDAQ:ASRT) shareholders will have a reason to smile today, with the covering analyst...
- 05/17/2020
|
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q1 2020 Results - Earnings Call Transcript
- Assertio Therapeutics, Inc. (NASDAQ:ASRT) Q1 2020 Earnings Conference Call May 11, 2020 8:30 AM ET Company Participants Max Nemmers - Director, Human Resources
- 05/11/2020
|
10-Q: ASSERTIO THERAPEUTICS, INC
- (EDGAR Online via COMTEX) --
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FORWARD-LOOKING INFORMATION...
- 05/11/2020
|
Assertio (ASRT) Beats Q1 Earnings and Revenue Estimates
- Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
Recap: Assertio Therapeutics Q1 Earnings
- Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 56.52% over the past year to $0.10, which beat the estimate of ($0.08).Revenue of $20,917,000 less by 63.89% from the same period last year, which beat the estimate of $11,300,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 11, 2020View more earnings on ASRTTime: 08:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/vryis85cTechnicals 52-week high: $4.92Company's 52-week low was at $0.55Price action over last quarter: Up 10.80%Company Description Assertio Therapeutics Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.See more from Benzinga * 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session * 20 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/11/2020
|
Assertio Therapeutics Announces First-Quarter 2020 Results
- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible.
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates The Merger Of Assertio Therapeutics, Inc.; Investors Are Encouraged To Contact The Firm
- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Assertio Therapeutics, Inc. (NASDAQ: ASRT) and Zyla Life Sciences is fair to Assertio shareholders.
- 05/09/2020
|
ASSERTIO MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Assertio Therapeutics, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm
- NEW YORK, NY / ACCESSWIRE / May 8, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Assertio Therapeutics, Inc. (NASDAQ:ASRT) and Zyla Life Sciences ...
- 05/09/2020
|
SHAREHOLDER ALERT: WeissLaw LLP Investigates Assertio Therapeutics, Inc.
- URGENT: STOCKHOLDER VOTE MAY 19, 2020
- 05/08/2020
|
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
- Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2020
|
Should You Buy This Biotech That Makes A Lower Risk Painkiller?
- A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.
- 04/21/2020
|
Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus
- Assertio Therapeutics, Inc. (“Assertio” or “the Company”) (ASRT) today announced the date of its 2020 Annual Meeting, which will be held as a virtual meeting on May 19, 2020. The Company also announced the mailing of a joint proxy statement/prospectus (the “Joint Proxy Statement/Prospectus”) to stockholders. At the 2020 Annual Meeting, the Company will ask its stockholders, among other things, to approve the issuance of shares to stockholders of Zyla Life Sciences (“Zyla”) in connection with the Company’s previously announced merger with Zyla (the “Merger”).
- 04/20/2020
|
Activist hedge fund Starboard pounces on U.S. companies in turmoil
- Most activist shareholders have refrained from challenging the boards of U.S. companies during this season of annual shareholder meetings, as businesses reel from the economic fallout of the coronavirus outbreak.
- 04/15/2020
|
UPDATE 1-Activist hedge fund Starboard pounces on U.S. companies in turmoil
- Most activist shareholders have refrained from challenging the boards of U.S. companies during this season of annual shareholder meetings, as businesses reel from the economic fallout of the coronavirus outbreak.
- 04/15/2020
|
Activist hedge fund Starboard pounces on U.S. companies in turmoil
- Most activist shareholders have refrained from challenging the boards of U.S. companies during this season of annual shareholder meetings, as businesses reel from the economic fallout of the coronavirus outbreak.
- 04/15/2020
|
Activist hedge fund Starboard pounces on U.S. companies in turmoil
- Most activist shareholders have refrained from challenging the boards of U.S. companies during this season of annual shareholder meetings, as businesses reel from the economic fallout of the coronavirus outbreak.
- 04/15/2020
|
Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024
- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (ASRT), today announced the completion and final results for its cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50% Senior Convertible Notes due 2021 (CUSIP:249908AA2) (“2021 Notes”) and $34,522,000 of its 5.00% Senior Convertible Notes due 2024 (CUSIP:04545LAA5) (“2024 Notes”, together with the 2021 Notes, the “Notes”). The Offers were made on the terms and subject to the conditions set forth in an Offer to Purchase dated March 11, 2020 (the “Offer to Purchase”) and expired at 11:59 p.m., New York City time, on April 7, 2020 (the “Expiration Time”). As of the Expiration Time of the Offers, $42,130,000 aggregate principal of 2021 Notes and $34,522,000 aggregate principal of 2024 Notes have been validly tendered and not validly withdrawn (the “Accepted Notes”).
- 04/08/2020
|
Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Have A Particularly Volatile Share Price?
- If you're interested in Assertio Therapeutics, Inc. (NASDAQ:ASRT), then you might want to consider its beta (a measure...
- 04/02/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
Wayne-based drug company enters into $17.5M merger deal
- Zyla Life Sciences (OTCQX: ZCOR), a Wayne-based specialty pharmaceutical company that focuses on non-opioid pain products, has entered into a definitive merger agreement with Assertio Therapeutics. Zyla will operate as a subsidiary of the new holding company.
- 03/17/2020
|
Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – WLTW, TTPH, ASRT, MEET
- NEW YORK, March 17, 2020 -- Halper Sadeh LLP, a global investor rights law firm, investigates whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP.
- 03/17/2020
|
Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products
- Assertio Therapeutics, Inc. (“Assertio” or “the Company”) (ASRT) and Zyla Life Sciences (“Zyla”) (ZCOR), today announced that they have entered into a definitive merger agreement (the “Agreement”). Under the terms of the Agreement, upon the effective time of the merger (the “Merger”), Zyla stockholders will be entitled to receive 2.5 shares of common stock of a newly-formed holding company for each share of Zyla common stock held and the newly combined company will retain the Assertio name and trade on Nasdaq under the ASRT ticker.
- 03/16/2020
|
PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End
- PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.
- 03/12/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV
- 03/11/2020
|
Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024
- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50% Senior Convertible Notes due 2021 (CUSIP:249908AA2) and $34,522,000 of its 5.00% Senior Convertible Notes due 2024 (CUSIP:04545LAA5) (together, the “Notes”). The Offers are being made on the terms and subject to the conditions set forth in an Offer to Purchase dated March 11, 2020 (the “Offer to Purchase”) and are scheduled to expire at 11:59 p.m., New York City time, on April 7, 2020 unless extended by the Company (the “Expiration Time”). Holders of the Notes who have tendered (and not validly withdrawn) their Notes at or prior to the Expiration Time will be entitled to receive in cash $995 per $1,000 principal amount of Notes validly tendered (and not validly withdrawn), plus accrued and unpaid interest on such Notes up to, but not including, the date the Offers are settled which is expected to be promptly following the expiration of the Offers.
- 03/11/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enzo Biochem, Inc. (NYSE: ENZ) * Centogene NV (NASDAQ: CNTG) * Inovio Pharmaceuticals Inc (NASDAQ:
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
- -- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and.
- 03/09/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news. View more earnings on IBBThe following are key catalysts in the unfolding week that a biotech
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
Assertio (ASRT) to Report Q4 Earnings: What's in Store?
- During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
- 02/24/2020
|
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
- 02/14/2020
|
Mid-Morning Market Update: Markets Open Lower; US Adds 225,000 Jobs For January
- Following the market opening Friday, the Dow traded down 0.65% to 29189.16 while the NASDAQ fell 0.59% to 9516.79. The S&P also fell, dropping 0.57% to 3,326.60.
Leading and...
- 02/07/2020
|
Bio Roundup: POTUS on Prices, a16z's Fund, Aimmune's Approval & More
- The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics:
- 02/07/2020
|
16 Healthcare Stocks Moving In Friday's Pre-Market Session
- Gainers
• Assertio Therapeutics, Inc. (NASDAQ:ASRT) stock increased by 57.7% to $1.64 during Friday's pre-market session.
• Seelos Therapeutics, Inc. (NASDAQ:SEEL)...
- 02/07/2020
|
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- 02/07/2020
|
5 Drug Manufacturers—Specialty & Generic Stocks Moving In Tuesday's After-Market Session
- Gainers
• Assertio Therapeutics, Inc. (NASDAQ:ASRT) stock moved upwards by 3.1% to $1.34 during Tuesday's after-market session.
Losers
• Durect, Inc. (NASDAQ:...
- 01/22/2020
|
DDD, NVTA among premarket gainers
- Adaptimmune Therapeutics PLC (NASDAQ:ADAP) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors.Verona Pharma PLC (NASDAQ:VRNA) +54% on positive ensifentrine data.Mereo BioPha
- 01/13/2020
|
5 Top NASDAQ Biotech and Pharma Stocks: Neoleukin Up | INN
- Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have moved their share prices.
- 12/16/2019
|
How to Make Money off America's Opioid Epidemic
- If the title of this article made you a bit uncomfortable, it certainly should. The amount of prescription pain killers used by Americans is beyond staggering. According to an article by CNBC, '80 percent of the global opioid supply is consumed in the United States' and in 2015 '300 million pain prescriptions were written' totaling a $24 billion market. So many people are on prescription painkillers now that more Americans use them than tobacco: Investors have been making a killing here - literally. In light of President Trump's war on the opioid abuse problem, it's now time for everyone to
- 08/14/2017
|
